1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch
  1. My Preqin
Book a demo

Wave Life Sciences Ltd.

Have updates for this profile?  Please contribute data

About Financials Deals
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2012

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2012 by co-founder Greg Verdine, Wave Life Sciences Ltd., a.k.a. Wave Life Sciences operates as a clinical-stage biotechnology company that focuses on designing, developing, and commercializing ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. In December 2023, Wave Life Sciences Ltd. raised USD 100 million in a private placement, selling 20 million shares at USD 5 per share on the Nasdaq Global Select Market under the ticker symbol WVE. As of May 2024, Paul Bolno is the CEO of the company. Wave Life Sciences leverages its proprietary PRISM platform to develop RNA medicines that treat a wide range of disorders. PRISM combines various modalities, innovative chemistry, and human genetics insights to create oligonucleotides designed to engage messenger RNA (mRNA) and address diseases by repairing, restoring, or reducing proteins. The platform allows for the modulation of transcriptional diversity, targeting different cell types, and utilizing established manufacturing and regulatory processes. The company’s key programs include WVE-006 for Alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease.
Current Investors
TEVA Pharmaceuticals, GlaxoSmithKline Plc, RA Capital Management

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development
Website
www.wavelifesciences.com
Company Stage
Mature
Total Amount Raised
Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin
31 Dec 2015
152,000
-
(19,298,000)
(12696.1%)
(18,704,000)
(12305.3%)
(19,200,000)
(12631.6%)
31 Dec 2016
1,485,000
877%
(55,327,000)
(3725.7%)
(54,543,000)
(3672.9%)
(55,401,000)
(3730.7%)
31 Dec 2017
3,704,000
149.4%
(102,580,000)
(2769.4%)
(100,633,000)
(2716.9%)
(102,035,000)
(2754.7%)
31 Dec 2018
14,414,000
289.1%
(159,523,000)
(1106.7%)
(154,732,000)
(1073.5%)
(146,653,000)
(1017.4%)
31 Dec 2019
15,983,000
10.9%
(208,317,000)
(1303.4%)
(199,116,000)
(1245.8%)
(193,638,000)
(1211.5%)
31 Dec 2020
31 Dec 2021
31 Dec 2022

Unlock the recent years of financials and more for Wave Life Sciences Ltd..

Request a demo to see more.

Deals

Deals Type
Private Placement/Follow on
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Completed Wave Life Sciences Ltd. 06 Dec 2023
Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo